Versartis, Inc. (NASDAQ:VSAR) Among Today's Most Volatile Stocks - Down by 87.38%

Versartis, Inc. (NASDAQ:VSAR) Among Today's Most Volatile Stocks - Down by 87.38%

8 funds opened positions while 42 raised stakes. Bessemer Group Inc Inc holds 0% or 217 shares in its portfolio. Driehaus Capital Mngmt Limited Liability invested in 0.14% or 211,079 shares. Clarivest Asset Management Ltd Limited Liability Company has 0.04% invested in Versartis Inc (NASDAQ:VSAR). New York State Common Retirement Fund owns 67,415 shares for 0% of their portfolio. Artal Grp Incorporated Sa reported 350,000 shares. Woodstock Corp owns 27,583 shares for 0.09% of their portfolio. 14,100 were reported by Numeric Limited Liability Company. Rhumbline Advisers now owns 35,388 shares of the biopharmaceutical company's stock valued at $618,000 after purchasing an additional 1,420 shares in the last quarter. Versartis Inc had 17 analyst reports since August 13, 2015 according to SRatingsIntel. Arrowstreet Cap Partnership stated it has 12,400 shares or 0% of all its holdings. On Tuesday, June 27 the stock rating was maintained by Piper Jaffray with "Buy". Jpmorgan Chase Communication reported 0% stake.

Since March 24, 2017, it had 0 insider buys, and 4 sales for $798,195 activity. Sphera Funds Mgmt Limited stated it has 1.12% in Versartis Inc (NASDAQ:VSAR). (NASDAQ:VSAR) is also considered oversold with an RSI (14) now at 19.44. This is 12.36 % from the last close price. Citigroup maintained the shares of VSAR in report on Thursday, August 11 with "Buy" rating. Therefore 89% are positive. Versartis Inc has $34 highest and $3 lowest target. Volume was up 369.32% over the stocks average daily volume. On September 22 Canaccord Genuity held the company rating at "Buy" but lowered the price target from $20.00 to $9.00. As per Friday, July 28, the company rating was maintained by Canaccord Genuity. Cowen and Company downgraded Versartis to a "market perform" rating in a research note on Friday. The hedge fund held 22,014 shares of the catalog and specialty distribution company at the end of 2016Q4, valued at $812,000, down from 36,690 at the end of the previous reported quarter. On September 22, 2017 the stock rating was changed to "Neutral" according to a PiperJaffray report down from the previous "Overweight" rating. On Thursday, April 7 the stock rating was initiated by Northland Capital with "Outperform". On September 22 Morgan Stanley kept the company rating at "Buy" but moved down the price target to $9.00 from $17.00. As per Tuesday, June 27, the company rating was maintained by Piper Jaffray.

The stock decreased 87.62% or $18.93 on September 22, reaching $2.67.

The biotech's shares were eviscerated, dropping more than 80% on the news in after-market trading.

(NASDAQ:VSAR) now has a beta of 2.76 indicating it is higher in volatility than the market as a whole. It has outperformed by 86.48% the S&P500. The value of the company's investment in Versartis, Inc. decreased from $3,005,000 to $873,000 a change of $2,132,000 for the reporting period. Analysts forecast EPS of $-0.68, up exactly $0.24 or 26.09 % from 2014's $-0.92 EPS.

Versartis Company Profile Versartis, Inc is an endocrine-focused biopharmaceutical company.

The stock is among the market's biggest losers today. The drug, a form of human growth hormone that seeks to treat growth-hormone deficiency, failed to demonstrate superiority to Genotropin, an offering from Pfizer Inc., in a study focusing on pediatric growth-hormone deficiency. It now has negative earnings.

The VELOCITY trial enrolled 137 naïve to treatment, pre-pubertal children with GHD, and was created to demonstrate non-inferiority of Somavaratan compared to Pfizer Inc.'s (PFE) Genotropin, a daily recombinant human growth hormone (rhGH) in pediatric growth hormone deficiency patients.



Other news